Non-industry sponsored (local) studies:
- Overcoming the negative effect of anti αGAL antibody formation in Fabry disease
- The Fabry Cardio Prediction Study
- Secondary pathophysiology in Fabry disease, Gaucher disease and ASMD
- The Fabry Exercise Intolerance Study
Multicenter clinical trials the AMC participates in:
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE) (CLOSED)
- Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL (R) (Agalsidase Alfa) (BRIDGE) (CLOSED)
- Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Diseasese (BRILLIANCE)
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY) (CLOSED)
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY OLE)
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (CARAT)